Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the new product, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product portfolio and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product mix, comprehensive channel network, and refined brand management [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]

Summary of Key Points Core Viewpoint - On January 15, 42 Hong Kong-listed companies conducted share buybacks, totaling 28.45 million shares and an aggregate amount of HKD 945 million [1]. Group 1: Major Companies Involved - Tencent Holdings repurchased 1.017 million shares for HKD 636 million, with a highest price of HKD 632.00 and a lowest price of HKD 619.00, bringing its total buyback amount for the year to HKD 6.358 billion [1][2]. - Xiaomi Group-W bought back 3.90 million shares for HKD 148 million, with a highest price of HKD 37.92 and a lowest price of HKD 37.86, totaling HKD 1.241 billion in buybacks for the year [1][2]. - Sunny Optical Technology repurchased 1.20 million shares for HKD 79.01 million, with a highest price of HKD 66.45 and a lowest price of HKD 65.25, accumulating HKD 382.43 million in buybacks this year [1][2]. Group 2: Buyback Amounts and Quantities - The highest buyback amount on January 15 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 148 million [1]. - In terms of share quantity, the largest buyback was by First Capital Holdings with 4.95 million shares, followed by Xiaomi Group-W with 3.90 million shares and Maple Leaf Education with 2.90 million shares [1][2]. Group 3: Additional Companies and Data - Other notable companies involved in buybacks include Giant Bio, AAC Technologies, and others, with varying amounts and share quantities [1][2][3]. - The buyback activity reflects a strategic move by these companies to enhance shareholder value amidst market conditions [1].

Major Events - Giant Bio (02367) received the Medical Device Registration Certificate from the National Medical Products Administration for its recombinant type I α1 collagen and sodium hyaluronate composite solution [1] - Jitu Express-W (01519) plans to subscribe for 226 million H shares of SF Holding and issue 822 million Class B shares to SF Holding [1] - Zijin Mining (02899) signed a cooperation and equity transfer agreement for the Shapingou Molybdenum Mine project [1] - Jiangxi Copper (00358) subsidiary signed an Investment Option Agreement with First Quantum for exploration cooperation in Kazakhstan's mining projects [1] - Derin Holdings (01709) received conditional approval from the CSRC for Derin Securities to provide virtual asset consulting services [1] - GAC Group (02238) subsidiary GAC Trumpchi received 100 million yuan in funding for industrial transformation and development [1] - Juteng International (03336) suspected of a cyber attack and has initiated a comprehensive investigation [1] Operating Performance - China Southern Airlines (01055) increased passenger capacity input by 11.89% year-on-year in December [1] - Air China (00753) reported a 10% year-on-year increase in passenger turnover in December [1] - China Eastern Airlines (00670) saw a 7.61% year-on-year increase in passenger turnover in December [1] - China Metallurgical Group (01618) new contract amount for 2025 is 1,113.6 billion yuan, a decrease of 10.8% year-on-year [1] - ZhongAn Online (06060) projected total original insurance premium income of approximately 35.643 billion yuan for 2025, an increase of 6.66% year-on-year [1] - China General Nuclear Power Corporation (01164) produced a total of 702.5 tons of natural uranium in the fourth quarter [1] - Jiuxing Holdings (01836) reported a 0.8% year-on-year increase in comprehensive income to 388.6 million USD in the fourth quarter [1] - Luoyang Molybdenum (03993) issued a profit warning, expecting annual net profit attributable to shareholders to be between 20 billion and 20.8 billion yuan, an increase of 47.80% to 53.71% year-on-year [1] - Chongqing Iron and Steel (01053) issued a profit warning, expecting a net loss of 2.5 billion to 2.8 billion yuan for 2025 [1] - Huiju Technology (01729) issued a profit warning, expecting annual net profit to increase by approximately 60% to 70% year-on-year [1]

| 日期 | 回购股数（万股） | 回购最高价（港元） | 回购最低价（港元） | 回购金额（万港元） | | --- | --- | --- | --- | --- | | 2026.01.15 | 40.00 | 36.100 | 35.440 | 1434.67 | | 2026.01.14 | 40.00 | 35.800 | 35.100 | 1415.00 | | 2026.01.13 | 40.00 | 36.200 | 35.640 | 1433.78 | | 2026.01.12 | 40.00 | 35.500 | 34.500 | 1400.29 | | 2026.01.09 | 40.00 | 34.580 | 34.240 | 1375.96 | | 2026.01.08 | 40.00 | 34.440 | 34.120 | 1371.06 | | 2026.01.07 | 40.00 | 34.680 | 34.300 | 1378.34 | | 2026.01.06 | 40.00 | 34.480 | 33.840 | 1366.93 | | 2026.01.05 | 40. ...

Core Viewpoint - The company, Juzi Biotechnology, announced that its wholly-owned subsidiary, Shaanxi Juzi Biotechnology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration of China for a recombinant type I α1 collagen and sodium hyaluronate composite solution product [1] Group 1 - The product is primarily composed of recombinant collagen and sodium hyaluronate [1] - It is intended for injection into the dermis to improve the smoothness of the cheek area [1]

巨子生物(02367)公布，2026年1月15日耗资约1434.67万港元回购40万股股份。 ...

智通财经APP讯，巨子生物(02367)公布，2026年1月15日耗资约1434.67万港元回购40万股股份。 ...

格隆汇1月15日丨巨子生物(02367.HK)发布公告，2026年1月15日耗资1434.7万港元回购40万股，回购价 格每股35.44-36.1港元。 ...